OPG, a member of the TNF receptor family, a physiological antagonist of the receptor activator of NF-κB Ligand (RANKL), and also known as osteoclastogenesis inhibitory-factor (OCIF), is a player in bone-related diseases, cancer, and neurodegenerative disorders and thus is a potential biomarker and a therapeutic target (Baud’huin et al., 2013) (Freeman et al., 2024) [112,113]. This evidence concerns the gene TNFRSF11B and cancer.